IS2012B - Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli - Google Patents

Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli

Info

Publication number
IS2012B
IS2012B IS5093A IS5093A IS2012B IS 2012 B IS2012 B IS 2012B IS 5093 A IS5093 A IS 5093A IS 5093 A IS5093 A IS 5093A IS 2012 B IS2012 B IS 2012B
Authority
IS
Iceland
Prior art keywords
treatment
quinoline
compounds useful
benign prostatic
prostatic hyperplasia
Prior art date
Application number
IS5093A
Other languages
English (en)
Other versions
IS5093A (is
Inventor
Nathan Abraham Fox David
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS5093A publication Critical patent/IS5093A/is
Publication of IS2012B publication Critical patent/IS2012B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
IS5093A 1997-01-11 1999-06-25 Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli IS2012B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9700504.5A GB9700504D0 (en) 1997-01-11 1997-01-11 Pharmaceutical compounds
PCT/EP1998/000143 WO1998030560A1 (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia

Publications (2)

Publication Number Publication Date
IS5093A IS5093A (is) 1999-06-25
IS2012B true IS2012B (is) 2005-05-13

Family

ID=10805838

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5093A IS2012B (is) 1997-01-11 1999-06-25 Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli

Country Status (45)

Country Link
US (4) US6169093B1 (is)
EP (1) EP0968208B1 (is)
JP (1) JP3357677B2 (is)
KR (1) KR100347472B1 (is)
CN (2) CN1093858C (is)
AP (1) AP819A (is)
AR (1) AR010396A1 (is)
AT (1) ATE242238T1 (is)
AU (1) AU724990B2 (is)
BG (1) BG63918B1 (is)
BR (1) BR9807068A (is)
CA (1) CA2277473C (is)
CZ (1) CZ295580B6 (is)
DE (1) DE69815313T2 (is)
DK (1) DK0968208T3 (is)
DZ (1) DZ2394A1 (is)
EA (1) EA002851B1 (is)
ES (1) ES2198695T3 (is)
GB (1) GB9700504D0 (is)
HK (2) HK1025327A1 (is)
HN (1) HN1998000002A (is)
HR (1) HRP980010B1 (is)
HU (1) HUP0000942A3 (is)
ID (1) ID21863A (is)
IL (1) IL130762A (is)
IS (1) IS2012B (is)
MA (1) MA26465A1 (is)
MY (1) MY119623A (is)
NO (1) NO318609B1 (is)
NZ (1) NZ336302A (is)
OA (1) OA11074A (is)
PA (1) PA8444301A1 (is)
PE (1) PE44499A1 (is)
PL (1) PL334678A1 (is)
PT (1) PT968208E (is)
SA (1) SA97180705B1 (is)
SI (1) SI0968208T1 (is)
SK (1) SK284779B6 (is)
TN (1) TNSN98004A1 (is)
TR (1) TR199901604T2 (is)
TW (1) TW444013B (is)
UA (1) UA62945C2 (is)
WO (1) WO1998030560A1 (is)
YU (1) YU31699A (is)
ZA (1) ZA98166B (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
WO2001064672A1 (en) * 2000-03-03 2001-09-07 Pfizer Limited 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs
MXPA03001777A (es) 2000-08-31 2003-06-04 Hoffmann La Roche Derivados de quinazolina como antagonistas adrenergicos alfa-1.
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
ATE295362T1 (de) * 2001-01-02 2005-05-15 Hoffmann La Roche Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten
GB0112061D0 (en) * 2001-05-18 2001-07-11 Pfizer Ltd Process for the production of quinazolines
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
MXPA05002004A (es) 2002-09-26 2005-04-28 Pfizer Derivados de pirazol.
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
ES2290726T3 (es) * 2003-07-02 2008-02-16 F. Hoffmann-La Roche Ag Derivados de quinazolina 5-sustituidos.
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
EP1745029A1 (en) 2004-04-30 2007-01-24 Warner-Lambert Company LLC Substituted morpholine compounds for the treatment of central nervous system disorders
WO2008084493A2 (en) * 2007-01-09 2008-07-17 Unichem Laboratories Limited A novel process for the preparation of 2-halo-4-aminoquinazolines
JP2009126785A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法
JP2009126784A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法。
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
BR112016021730B1 (pt) * 2014-03-24 2022-09-06 Guangdong Zhongsheng Pharmaceutical Co., Ltd Derivados de quinolina como inibidores de smo

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875506A (en) * 1907-03-19 1907-12-31 Berry H Collins Guiding attachment for penholders.
GB1390015A (en) * 1971-05-07 1975-04-09 Koninklijke Pharma Fab Nv 4-amino-quinazoline compounds
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
GB9526546D0 (en) 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
US20020040028A1 (en) 2002-04-04
HK1054389A1 (en) 2003-11-28
EP0968208B1 (en) 2003-06-04
AU724990B2 (en) 2000-10-05
CZ295580B6 (cs) 2005-08-17
AP9801175A0 (en) 1998-01-31
CN1403453A (zh) 2003-03-19
HK1025327A1 (en) 2000-11-10
CA2277473C (en) 2003-08-12
KR20000070022A (ko) 2000-11-25
EA199900531A1 (ru) 2000-02-28
EA002851B1 (ru) 2002-10-31
US6521629B2 (en) 2003-02-18
IS5093A (is) 1999-06-25
US6653302B2 (en) 2003-11-25
WO1998030560A1 (en) 1998-07-16
SA97180705B1 (ar) 2005-12-26
CN1093858C (zh) 2002-11-06
SK284779B6 (sk) 2005-11-03
JP3357677B2 (ja) 2002-12-16
ATE242238T1 (de) 2003-06-15
US20030130259A1 (en) 2003-07-10
HRP980010B1 (en) 2002-06-30
DE69815313D1 (de) 2003-07-10
OA11074A (en) 2002-03-13
ES2198695T3 (es) 2004-02-01
GB9700504D0 (en) 1997-02-26
DE69815313T2 (de) 2003-12-11
TNSN98004A1 (fr) 2005-03-15
KR100347472B1 (ko) 2002-08-07
BR9807068A (pt) 2000-05-02
AU6208898A (en) 1998-08-03
ZA98166B (en) 1999-07-09
SK90799A3 (en) 2001-03-12
CN1191249C (zh) 2005-03-02
PL334678A1 (en) 2000-03-13
BG103560A (en) 2000-06-30
TR199901604T2 (xx) 1999-12-21
NO993396L (no) 1999-07-09
PE44499A1 (es) 1999-05-06
HK1054389B (zh) 2005-10-14
PT968208E (pt) 2003-09-30
AP819A (en) 2000-04-03
IL130762A (en) 2005-12-18
MA26465A1 (fr) 2004-12-20
NZ336302A (en) 2000-08-25
CZ9902436A3 (cs) 2000-10-11
EP0968208A1 (en) 2000-01-05
PA8444301A1 (es) 2000-05-24
IL130762A0 (en) 2001-01-28
NO993396D0 (no) 1999-07-09
UA62945C2 (en) 2004-01-15
US6365599B1 (en) 2002-04-02
JP2000507966A (ja) 2000-06-27
AR010396A1 (es) 2000-06-07
DZ2394A1 (fr) 2003-06-04
HN1998000002A (es) 1999-01-08
SI0968208T1 (en) 2003-10-31
HUP0000942A3 (en) 2002-06-28
MY119623A (en) 2005-06-30
CA2277473A1 (en) 1998-07-16
US6169093B1 (en) 2001-01-02
YU31699A (sh) 2001-07-10
HUP0000942A2 (hu) 2001-04-28
TW444013B (en) 2001-07-01
ID21863A (id) 1999-08-05
CN1243513A (zh) 2000-02-02
HRP980010A2 (en) 1998-10-31
DK0968208T3 (da) 2003-07-28
NO318609B1 (no) 2005-04-18
BG63918B1 (bg) 2003-06-30

Similar Documents

Publication Publication Date Title
IS2012B (is) Kínólín og kínasólín efnasambönd nytsamleg í meðferð, einkum til að meðhöndla góðkynja vefjaauka í blöðruhálskirtli
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
IS4731A (is) Kínólín og kínazólín efnasambönd nytsamleg í meðferð
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
AU1657097A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
NO995518L (no) Arylsubstituerte piperaziner brukbare ved behandling av benign prostatisk hyperplasi
HK1030776A1 (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
ZA982819B (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
EP1435913A4 (en) METHOD OF TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER BENCH PROSTATIC PATHOLOGIES
BR9608912A (pt) Agonistas de meletonina para o tratamento de hiperplasia prostática benigna
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia
AU2003204320A1 (en) Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia